Related references
Note: Only part of the references are listed.Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
Prudence A. Francis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
Olivia Pagani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes
Patrick Maisonneuve et al.
BREAST CANCER RESEARCH (2014)
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2013)
Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trials
Meredith M. Regan et al.
BREAST (2013)
Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial
John M. S. Bartlett et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
C. Davies et al.
LANCET (2011)
Evaluation of Treatment-Effect Heterogeneity Using Biomarkers Measured on a Continuous Scale: Subpopulation Treatment Effect Pattern Plot
Ann A. Lazar et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2009)
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial
Mitch Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole
Giuseppe Viale et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer:: BIG 1-98
Giuseppe Viale et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Re-evaluating adjuvant breast cancer trials:: Assessing hormone receptor status by immunohistochemical versus extraction assays
Meredith M. Regan et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients
Maria Stendahl et al.
CLINICAL CANCER RESEARCH (2006)
Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance
G Arpino et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer
LC Collins et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2005)
Patterns of treatment effects in subsets of patients in clinical trials
M Bonetti et al.
BIOSTATISTICS (2004)
Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer
M Colleoni et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
